A Randomized, Double-Blind, 3-arm Parallel Study to Compare PK, Safety, IMM and Tolerability of MB05, EU-sourced Synagis® and US-sourced Synagis®, as a Single Dose Intramuscular Injection in Healthy Volunteers.
Phase: PHASE1
Conditions: Healthy Volunteers
Sponsor: mAbxience Research S.L.

Protocol Title: 
Pharmacokinetic Study Comparing MB05 
(Proposed Palivizumab Biosimilar), EU-sourced 
Synagis® and US-sourced Synagis® in Healthy 
Volunteers.
NCT Number: 
NCT05121246
Protocol version 
date: 
Version 2.0, 07 June 2022